ACVR2B-eiwit (C-human IgG1-Fc, menselijk)

ACVR2B

ActR-IIB, ACTRIIB, HTX4

C-human IgG1-Fc

< 1.0 EU per μg of the protein as determined by the LAL method

≥ 97 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.

1. Measured by its ability to neutralize Activin-mediated inhibition on MPC11 cell proliferation. The ED50 for this effect is typically 0.02-0.1 μg/mL in the presence of 10 ng/mL recombinant Activin A (Routinely tested) . 2. Immobilized Recombinant Human/Mouse/Rat/Cynomolgus/Rhesus Activin A/INHBA Protein (Cat: 10429-HNAH) at 2 μg/mL (100 μl/well) can bind Recombinant Human ACVR2B / ActivinR-IIB Protein (ECD, Fc Tag) (Cat: 10229-H02H), the EC50 is 1.5-4.5 ng/mL (QC tested) . 3.Immobilized Recombinant Human/Mouse/Rat/Cynomolgus/Rhesus Activin A/INHBA Protein (Cat: 10429-HNAH) at 5 μg/mL (100 μL/well) can bind Recombinant Human ACVR2B / ActivinR-IIB Protein (ECD, Fc Tag) (Cat: 10229-H02H), the EC50 is 4.6 ng/mL (Routinely tested) .

Met1-Thr134

The recombinant human ACVR2B/Fc chimera is a disulfide-linked homodimer generated after removal of the signal peptide. The reduced monomer comprises 354 amino acids and predicts a molecular mass of 40.0 kDa. As a result of glycosylation, the monomer migrates as an approximately 60-65 kDa protein in SDS-PAGE under reducing conditions.

Human